Navigating Antitrust Risks When Responding to Tariffs

United States: Pharmaceutical Antitrust 2025

ABA 2024 Antitrust Spring Meeting

Federal Trade Commission Likely to Expand Labor Enforcement to Worker-Misclassification Issues

Uncertainty Remains More Than One Year After the FTC Announces New “Unfair Methods of Competition” Policy

States do-it-themselves: amid spotty federal enforcement, state legislatures are revamping right-to-repair laws at an unprecedented pace

United States: Pharmaceutical Antitrust 2024

Four US Antitrust Conduct and Enforcement Trends for LatAm Companies to Watch

5 Steps Cos. Can Take Amid Surge In 'Right To Repair' Actions

Four Takeaways From The FTC’s Unprecedented Crackdown On Noncompete Agreements

United States: Pharmaceutical Antitrust 2023

Federal District Court holds that California's anti reverse payment law is enforceable, but only against settlements "negotiated, completed, or entered" in California

United States: Pharmaceutical Antitrust 2022

New York’s Sweeping New Antitrust Bill—Requiring NY State Premerger Notification ($9.2M Filing Threshold) and Prohibiting “Abuse of Dominance”—Inches Closer to Becoming Law

How Cos. Can Weather Growing DOJ Labor Antitrust Scrutiny

Misguided Sensipar Ruling Threatens Patent Settlements

FTC Publishes Annual MMA Report—Continues to Scrutinize Pharma Patent Settlements

United States: Pharmaceutical Antitrust 2021